Candriam S.C.A. Has $9.32 Million Stock Position in Cencora, Inc. $COR

Candriam S.C.A. lifted its stake in shares of Cencora, Inc. (NYSE:COR) by 326.7% during the second quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 31,095 shares of the company’s stock after purchasing an additional 23,808 shares during the period. Candriam S.C.A.’s holdings in Cencora were worth $9,324,000 at the end of the most recent quarter.

Several other large investors also recently made changes to their positions in COR. Voleon Capital Management LP bought a new stake in shares of Cencora in the first quarter valued at approximately $3,111,000. Focus Partners Wealth increased its stake in Cencora by 25.8% during the 1st quarter. Focus Partners Wealth now owns 5,715 shares of the company’s stock worth $1,589,000 after acquiring an additional 1,171 shares during the period. Acadian Asset Management LLC raised its holdings in Cencora by 947.5% in the 2nd quarter. Acadian Asset Management LLC now owns 257,082 shares of the company’s stock valued at $77,069,000 after acquiring an additional 232,539 shares in the last quarter. Martin Capital Partners LLC lifted its position in shares of Cencora by 205.2% during the 2nd quarter. Martin Capital Partners LLC now owns 3,784 shares of the company’s stock valued at $1,135,000 after acquiring an additional 2,544 shares during the period. Finally, Fiduciary Alliance LLC acquired a new stake in shares of Cencora during the 2nd quarter worth $262,000. Institutional investors and hedge funds own 97.52% of the company’s stock.

Analyst Ratings Changes

Several equities research analysts recently weighed in on the stock. UBS Group upped their price objective on shares of Cencora from $380.00 to $415.00 and gave the stock a “buy” rating in a research report on Friday, November 7th. Evercore ISI set a $400.00 target price on shares of Cencora and gave the company an “outperform” rating in a research report on Thursday, November 6th. Mizuho increased their price target on shares of Cencora from $340.00 to $380.00 and gave the stock an “outperform” rating in a research report on Thursday, November 6th. Wells Fargo & Company boosted their price objective on shares of Cencora from $354.00 to $405.00 and gave the company an “overweight” rating in a research report on Tuesday. Finally, TD Cowen upped their target price on Cencora from $350.00 to $400.00 and gave the stock a “buy” rating in a research note on Monday, November 10th. Nine equities research analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $371.09.

Cencora Price Performance

Shares of NYSE:COR opened at $361.97 on Friday. Cencora, Inc. has a one year low of $223.92 and a one year high of $369.00. The company has a debt-to-equity ratio of 3.64, a current ratio of 0.90 and a quick ratio of 0.53. The company has a market cap of $70.18 billion, a price-to-earnings ratio of 37.24, a PEG ratio of 1.56 and a beta of 0.63. The firm has a 50 day simple moving average of $321.35 and a 200 day simple moving average of $302.08.

Cencora (NYSE:COR) last posted its earnings results on Wednesday, November 5th. The company reported $3.84 earnings per share for the quarter, topping analysts’ consensus estimates of $3.79 by $0.05. Cencora had a net margin of 0.60% and a return on equity of 267.36%. The firm had revenue of $83.73 billion for the quarter, compared to analysts’ expectations of $83.36 billion. During the same quarter in the previous year, the firm posted $3.34 earnings per share. The company’s revenue was up 5.9% on a year-over-year basis. Cencora has set its FY 2026 guidance at 17.450-17.75 EPS. Research analysts predict that Cencora, Inc. will post 15.37 earnings per share for the current fiscal year.

Cencora Increases Dividend

The company also recently announced a quarterly dividend, which will be paid on Monday, December 1st. Shareholders of record on Friday, November 14th will be given a $0.60 dividend. This is a boost from Cencora’s previous quarterly dividend of $0.55. This represents a $2.40 annualized dividend and a yield of 0.7%. The ex-dividend date is Friday, November 14th. Cencora’s dividend payout ratio is 30.19%.

Insider Transactions at Cencora

In other news, CEO Robert P. Mauch sold 5,097 shares of the business’s stock in a transaction dated Monday, October 20th. The stock was sold at an average price of $326.80, for a total transaction of $1,665,699.60. Following the sale, the chief executive officer directly owned 37,940 shares in the company, valued at approximately $12,398,792. The trade was a 11.84% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, Chairman Steven H. Collis sold 31,350 shares of the company’s stock in a transaction that occurred on Tuesday, September 16th. The shares were sold at an average price of $289.86, for a total value of $9,087,111.00. Following the completion of the transaction, the chairman directly owned 305,913 shares of the company’s stock, valued at $88,671,942.18. This represents a 9.30% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold 41,544 shares of company stock worth $12,230,941 over the last three months. Insiders own 10.80% of the company’s stock.

Cencora Company Profile

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.